VRNA vs. LLY

Last updated Apr 1, 2026

Compare and contrast key facts about Verona Pharma plc (VRNA) and Eli Lilly and Company (LLY).

Performance

VRNA vs. LLY - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Verona Pharma plc (VRNA) and Eli Lilly and Company (LLY). The values are adjusted to include any dividend payments, if applicable.

VRNA vs. LLY - Yearly Performance Comparison

	2026 (YTD)	2025	2024	2023	2022	2021	2020	2019	2018	2017
VRNA Verona Pharma plc	0.00%	130.21%	133.60%	-23.92%	288.84%	-4.00%	21.74%	-40.41%	-18.71%	-12.07%
LLY Eli Lilly and Company	-14.27%	40.25%	33.30%	60.91%	34.26%	66.08%	31.04%	16.14%	40.45%	5.85%

Fundamentals

Market Cap VRNA : $9.72B LLY : $825.96B
EPS VRNA : -$0.69 LLY : $22.96
PS Ratio VRNA : 57.97 LLY : 12.68
PB Ratio VRNA : 34.92 LLY : 31.13
Total Revenue (TTM) VRNA : $167.65M LLY : $65.18B
Gross Profit (TTM) VRNA : $159.52M LLY : $54.62B
EBITDA (TTM) VRNA : -$40.86M LLY : $27.94B

Returns By Period

VRNA

• 1D: —
• 1M: —
• YTD: —
• 6M: —
• 1Y: —
• 3Y*: —
• 5Y*: —
• 10Y*: —

LLY

• 1D: 3.74%
• 1M: -12.57%
• YTD: -14.27%
• 6M: 20.93%
• 1Y: 12.19%
• 3Y*: 39.90%
• 5Y*: 39.16%
• 10Y*: 30.92%

*Multi-year figures are annualized to reflect compound growth (CAGR)

Return for Risk

VRNA vs. LLY — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

LLY

LLY Risk / Return Rank: 51
LLY Sharpe Ratio Rank: 53
LLY Sortino Ratio Rank: 48
LLY Omega Ratio Rank: 49
LLY Calmar Ratio Rank: 53
LLY Martin Ratio Rank: 54

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

VRNA vs. LLY - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Verona Pharma plc (VRNA) and Eli Lilly and Company (LLY). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

Risk / return metrics aren't available yet — we need at least 12 months of trading data to calculate them.

Sharpe Ratios by Period

	VRNA	LLY	Difference
Sharpe Ratio (1Y) Calculated over the trailing 1-year period	—	0.29	—
Sharpe Ratio (5Y) Calculated over the trailing 5-year period	—	1.23	—
Sharpe Ratio (10Y) Calculated over the trailing 10-year period	—	1.04	—
Sharpe Ratio (All Time) Calculated using the full available price history	—	0.56	—

Correlation

The correlation between VRNA and LLY is 0.11, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.

Dividends

VRNA vs. LLY - Dividend Comparison

VRNA has not paid dividends to shareholders, while LLY's dividend yield for the trailing twelve months is around 0.68%.

	TTM	2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015
VRNA Verona Pharma plc	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
LLY Eli Lilly and Company	0.68%	0.56%	0.67%	0.78%	1.07%	1.23%	1.75%	1.96%	1.94%	2.46%	2.77%	2.37%

Drawdowns

Drawdown Indicators

	VRNA	LLY	Difference
Max Drawdown Largest peak-to-trough decline	—	-68.24%	—
Max Drawdown (1Y) Largest decline over 1 year	—	-30.26%	—
Max Drawdown (5Y) Largest decline over 5 years	—	-34.48%	—
Max Drawdown (10Y) Largest decline over 10 years	—	-34.48%	—
Current Drawdown Current decline from peak	—	-17.00%	—
Average Drawdown Average peak-to-trough decline	—	-19.25%	—
Ulcer Index Depth and duration of drawdowns from previous peaks	—	12.39%	—

Volatility

Volatility by Period

	VRNA	LLY	Difference
Volatility (1M) Calculated over the trailing 1-month period	—	9.04%	—
Volatility (6M) Calculated over the trailing 6-month period	—	26.21%	—
Volatility (1Y) Calculated over the trailing 1-year period	—	42.44%	—
Volatility (5Y) Calculated over the trailing 5-year period, annualized	—	32.14%	—
Volatility (10Y) Calculated over the trailing 10-year period, annualized	—	29.80%	—

Financials

VRNA vs. LLY - Profitability Comparison

The chart below illustrates the profitability comparison between Verona Pharma plc and Eli Lilly and Company over time, highlighting three key metrics: Gross Profit Margin, Operating Margin, and Net Profit Margin.

VRNA - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Apr 2026, Verona Pharma plc reported a gross profit of 71.68M and revenue of 75.14M. Therefore, the gross margin over that period was 95.4%.

LLY - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Apr 2026, Eli Lilly and Company reported a gross profit of 16.41B and revenue of 19.29B. Therefore, the gross margin over that period was 85.1%.

VRNA - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Apr 2026, Verona Pharma plc reported an operating income of 9.69M and revenue of 75.14M, resulting in an operating margin of 12.9%.

LLY - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Apr 2026, Eli Lilly and Company reported an operating income of 8.78B and revenue of 19.29B, resulting in an operating margin of 45.5%.

VRNA - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Apr 2026, Verona Pharma plc reported a net income of 8.69M and revenue of 75.14M, resulting in a net margin of 11.6%.

LLY - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Apr 2026, Eli Lilly and Company reported a net income of 6.64B and revenue of 19.29B, resulting in a net margin of 34.4%.